◆ Market Terminal AILook up a stock

ANI Pharmaceuticals, Inc. (ANIP)

Healthcare · Drug Manufacturers - Specialty & Generic · Small-cap · updated October 16, 2026

NOT A BUY TODAY
What this means. ANI Pharmaceuticals, Inc. is a strong business by our measures, its shares look fairly priced, and its share price has been weak.
Value64
Quality67
Price trend32
Overall59
528 of 2764rank among the US stocks we score (our core model buys the top 15)
81%of US stocks we score rank below it

Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.

The business in numbers

Fiscal year to December 2025, from the company's annual filing with the SEC.

Salesyearly sales$883.4M
Sales growthchange from the year before+43.8%
Operating marginshare of sales left after running the business12.6%
Net marginshare of sales kept as profit8.8%
Free-cash-flow marginspare cash generated per $100 of sales19.4%
Return on invested capitalprofit made on each $100 put into the business10.3%
Return on equityprofit vs. shareholders' accounting value14.4%
Debt / equitydebt vs. shareholders' accounting value0.57
Interest coverhow many times profit covers interest payments3.4x
Change in share countnegative = the company is buying back its shares+9.9%

Insider trades, last 90 days

1 insider sold $232K (all under pre-arranged plans) on the open market.

Carey Stephen P.Svp & CfoSold (plan)Jul 292,850 shat $81.36 · $232K

From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.

Higher-scoring in the same industry

Interactive lookupGet the Ledger every Monday

Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy